Videos

Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.

The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.

Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.

Matthew A. Powell, MD, shares an overview of the systemic treatment options for patients with relapsed or metastatic endometrial cancer and the factors he considers when selecting an appropriate frontline therapy.

Arlene Siefker-Radtke, MD, discusses the nuanced treatment journey of a 73-year-old man with metastatic bladder cancer, highlighting the challenges and evolving strategies in his case.

Dr Matthew A. Powell reviews the study design and key endpoints of the RUBY trial in dMMR endometrial cancer and explains the potential clinical implications of the data.

Medical expert provides an overview of the recommended biomarker testing for endometrial cancer and the frontline treatment options available for patients with dMMR/MSI-high endometrial cancer.

Warren C. Swegal, MD, discusses the role of cabozantinib (Cabometyx) for patients with radioactive iodine (RAI)–refractory differentiated thyroid cancer (DTC).

Aaron T. Gerds, MD, MS, provides advice to community oncologists on how to utilize momelotinib for patients with myelofibrosis.

Closing out their program on HR+/HER2- metastatic breast cancer, panelists look toward future evolutions in the treatment landscape.

Adding immunotherapy to chemotherapy is the new standard-of-care treatment for advanced or recurrent endometrial cancer, according to Eirwen Miller, MD.

Skye Montoya, discusses research that she was a part of on mechanisms of resistance to noncovalent Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia.

Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.

Hatem Soliman, MD, discusses second- and third-line strategies being used for the treatment of patients with HER2-positive metastatic breast cancer.

Aaron T. Gerds, MD, MS, highlights exciting treatment options on the horizon for patients with myelofibrosis.

Aaron T. Gerds, MD, MS, explains the current remaining unmet needs in the treatment of patients with myelofibrosis.

Aaron T. Gerds, MD, MS, details the current treatment options available for patients with high-risk myelofibrosis, and reviews the criteria for risk stratification.

The push for more screening of patients with a history of smoking is providing oncologists the ability to catch small cell lung cancers earlier and potentially change the prognosis of the disease.

Robert J. Motzer, MD, discusses unmet needs and looks to the future of treatment for patients with clear cell renal cell carcinoma.

Expert perspectives on how adverse events differ among the available clear cell renal cell carcinoma treatment options.

Dr Jamie L. Koprivnikar comments on the currently unmet needs for patients with low-risk myelodysplastic syndrome in the front-line setting.

Jamie L. Koprivnikar, MD, details how her treatment approaches differ for patients with low-risk versus high-risk myelodysplastic syndrome.

Nathan Bahary, MD, PhD, discusses how Allegheny Health Network has been able to combat the recent chemotherapy drug shortages seen nationwide.

Joshua K. Sabari, MD, discusses the importance of targeting the KRAS biomarker and what inhibitors currently exist for patients with KRAS G12C-mutant advanced solid tumors.

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Michael Wang, MD, discusses where unmet needs still exist for patients with relapsed/refractory mantle cell lymphoma.

Petros Grivas, MD, PhD, discusses the design and end points of the phase 2 KEYNOTE-057 trial.

Ruchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.

Key opinion leaders on breast cancer management share insight on the evolving role of antibody drug conjugates and their potential impact on care.

Following her review of TROPiCS-02, Joyce O’Shaughnessy, MD, shares data from the DESTINY-Breast04 study of T-DXd in HER2-low metastatic breast cancer.